(Bloomberg) -- Juul Labs Inc. said it's continuing to sell its vaping products that are at the center of an ongoing standoff with the Food and Drug Administration.
The agency banned Juul's products on June 23, citing a lack of evidence demonstrating the overall safety of the company's products and noting their “disproportionate role in the rise in youth vaping.” The next day, Juul won an emergency court order temporarily blocking the FDA's decision. In a separate action, the FDA administratively suspended its ban on Tuesday after determining there were additional scientific issues it needed to review, effectively allowing the company to continue selling its products.
“We continue to offer our products to adult smokers while we pursue the agency's internal review process,” Joe Murillo, Juul's chief regulatory officer, said in an email. “We remain confident in the quality and substance of our applications and believe that ultimately we will be able to demonstrate that our products do in fact meet the statutory standard of being appropriate for the protection of the public health.”
Late Wednesday, the two sides asked to put the court case on hold while the FDA conducts its administrative review.
The company still lacks authorization to market, sell, or ship its products, an FDA spokesperson said. The agency doesn't intend to take enforcement action against the products subject to the marketing denial order while the administrative stay is in place, according to the filing.
Shares of Altria Group Inc., the Marlboro cigarette maker that paid $12.8 billion for a 35% stake in Juul in 2018, fell 1.3% at the close in New York.
(Updates with joint request to put court case on hold)
More stories like this are available on bloomberg.com
©2022 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
